Podcast

Pharmacy Focus: Oncology Edition - An Update on Prostate Cancer and the Growing Role of Pharmacists

As treatments improve and prostate cancer potentially becomes more of a chronic illness, pharmacists have a chance to shine.

This month, we spoke with Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, director of pharmacy cancer care services at Mayo Clinic, to learn about the latest updates and pipeline treatments in prostate cancer. As treatments improve and prostate cancer potentially becomes more of a chronic illness, Soefje said pharmacists have a chance to shine.

Related Videos
3d rendering of Bispecific antibodies or BsAbs have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously
Related Content
Immune Checkpoint Inhibitor-Associated Nephritis: A Case of Nivolumab-Induced Acute Kidney Injury in a Patient with Urothelial Carcinoma
December 20th 2024

Immune Checkpoint Inhibitor-Associated Nephritis: A Case of Nivolumab-Induced Acute Kidney Injury in a Patient with Urothelial Carcinoma

George DeMaagd, PharmD, BCPS Gregory Franz, MD, MPH Zachery Halford, PharmD, BCOP, BCPPS
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Depiction of colorectal cancer tumor growth Image Credit: © Dr_Microbe - stock.adobe.com
December 18th 2024

Chronic Inflammation Driven by Diet May Contribute to Colorectal Cancer, Study Finds

Alexandra Gerlach, Associate Editor
Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes
November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP
Small Cell Lung Cancer Cells: These small, round cells in the lungs divide rapidly and are known for early metastasis, resulting in highly aggressive cancer.
December 17th 2024

Sacituzumab Govitecan-hziy Receives FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer Treatment

Luke Halpern, Assistant Editor
FDA approval stamp -- Image credit: Olivier Le Moal | stock.adobe.com
December 16th 2024

FDA Approves Cosibelimab-Ipdl for Adult Patients with mCSCC or laCSCC

Gillian McGovern, Assistant Editor